Ustekinumab as Induction and Maintenance Therapy for Crohn’s DiseaseBrian G. Feagan, Paul Rutgeerts, William J. Sandborn et al.|New England Journal of Medicine|2016Cited by 1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisBruce E. Sands, Colleen Marano, William J. Sandborn et al.|New England Journal of Medicine|2019Cited by 1.2k
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Toshifumi Hibi∥ et al.|Gastroenterology|2013Cited by 938
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative ColitisWilliam J. Sandborn, Paul Rutgeerts, Brian G. Feagan et al.|Gastroenterology|2013Cited by 725
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative ColitisOmoniyi J. Adedokun, Walter Reinisch, William J. Sandborn et al.|Gastroenterology|2014Cited by 339